4 studies found for:    22658128 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Condition: Neoplasms
Intervention: Genetic: Blood and tumor samples
2 Not yet recruiting Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).
Condition: Non-Small-Cell Lung Carcinoma (NSCLC)
Interventions: Biological: MEDI4736;   Biological: MEDI4736+Tremelimumab;   Drug: Paclitaxel + Carboplatin;   Drug: Gemcitabine + Cisplatin;   Drug: Gemcitabine + Carboplatin;   Drug: Pemetrexed + Cisplatin;   Drug: Pemetrexed + Carboplatin;   Biological: Tremelimumab
3 Active, not recruiting Multiple Ascending Dose (MDX1105-01)
Condition: Cancer, Multiple Indications
Intervention: Biological: Anti-PDL-1 antibody
4 Recruiting Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer
Conditions: Head and Neck Squamous Cell Carcinoma;   Metastatic Renal Cell Cancer;   Recurrent Head and Neck Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Skin Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Skin Melanoma
Interventions: Radiation: Radiation Therapy (RT);   Drug: MK-3475

Indicates status has not been verified in more than two years